Comparison of the efficacy of oxybutynin and phenazopyridine and celecoxib with placebo in the treatment of urinary tract symptoms after BCG therapy in bladder tumors patients

The efficacy of oxybutynin and phenazopyridine and celecoxib and placebo in controlling BCG-induced urinary and systemic symptoms and obtaining the correct protocol for BCG administration is.

In this study, 120 patients with bladder tumor and candidate for treatment of intercostal BCG who were admitted to the Hasheminejad Hospital in Tehran were selected. The participants were randomly divided into four groups of 30, randomly assigned to each group The patients underwent the treatment at the same time during the six weeks of BCG treatment, and weekly signs were recorded in the designed questionnaire and were prepared for statistical analysis.

This study is a randomized clinical trial that will be done by parallel groups in four groups. The study population was adult bladder tumor candidate candidate for treatment of Bacillus Calmette–Guérin (BCG) as a 6-week induction protocol that was administered to the Hashemi Nejad Clinic during the year 1395

inclution Criteria of the study are bladder tumor that candidate for Bacillus Calmette–Guérin (BCG) Therapy and aged over 18 years. Exclution criteria include history of pelvic surgery, severe urinary tract symptoms, overactive bladder, complete urinary incontinence, traumatic catheterization , active TB symptoms

In accordance with the pharmaceutical company, all treatments in the same coating were prepared in a capsule form that were not indistinguishable, and one of the groups was treated with oxybutynin 10 mg daily and the next group of phenazoperidine three times daily and the next group of celecoxib 100 mg and the last group received placebo Within 6 weeks will be tracked

dysuria, frequency, urgency

Patients were divided into four group with random allocation process. The randomized blocks were randomly assigned to the researcher by the design consultant in sealed envelopes. . The creation of a randomized table with the STATA software and its output will be random letters A, B, C, D for treatment groups 1 to 4. After qualifying for inclusion in the study and lack of exclusion criteria by one of the researchers, the envelope designation for the candidate number of the candidate for treatment of BCG is opened and the type of treatment A, B, C, D specified and the person will be treated once a week. And the drug will be delivered to the patient. In co-ordination with the pharmaceutical company, all treatments in the same coatings are provided in capsule form that can not be differentiated

Patients were selected according to a randomized table, and the presenter and the investigator were not included in the selected medication. In the case of a person in the study, the medication was placed in the same coat of coat. The designer was blinded to the use of a randomized table and sealed envelopes in which the names of the drugs were used. In the case of the researcher, according to the coding of the participating groups and the naming of groups with blind numbers.